Immunovant Statistics
Total Valuation
Immunovant has a market cap or net worth of $5.21 billion. The enterprise value is $4.12 billion.
Important Dates
The next estimated earnings date is Thursday, May 28, 2026, before market open.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Immunovant has 203.53 million shares outstanding. The number of shares has increased by 18.37% in one year.
| Current Share Class | 203.53M |
| Shares Outstanding | 203.53M |
| Shares Change (YoY) | +18.37% |
| Shares Change (QoQ) | +4.53% |
| Owned by Insiders (%) | 0.60% |
| Owned by Institutions (%) | 47.75% |
| Float | 77.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.18 |
| P/TBV Ratio | 5.18 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.74
| Current Ratio | 15.74 |
| Quick Ratio | 15.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.35% and return on invested capital (ROIC) is -45.49%.
| Return on Equity (ROE) | -69.35% |
| Return on Assets (ROA) | -41.33% |
| Return on Invested Capital (ROIC) | -45.49% |
| Return on Capital Employed (ROCE) | -49.40% |
| Weighted Average Cost of Capital (WACC) | 7.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.28M |
| Employee Count | 362 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Immunovant has paid $3.64 million in taxes.
| Income Tax | 3.64M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +71.12% in the last 52 weeks. The beta is 0.67, so Immunovant's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +71.12% |
| 50-Day Moving Average | 25.61 |
| 200-Day Moving Average | 21.45 |
| Relative Strength Index (RSI) | 50.76 |
| Average Volume (20 Days) | 1,418,318 |
Short Selling Information
The latest short interest is 18.43 million, so 9.06% of the outstanding shares have been sold short.
| Short Interest | 18.43M |
| Short Previous Month | 16.57M |
| Short % of Shares Out | 9.06% |
| Short % of Float | 23.79% |
| Short Ratio (days to cover) | 15.86 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -487.17M |
| Pretax Income | -460.56M |
| Net Income | -464.20M |
| EBITDA | -486.75M |
| EBIT | -487.17M |
| Earnings Per Share (EPS) | -$2.68 |
Full Income StatementBalance Sheet
The company has $994.53 million in cash and n/a in debt, with a net cash position of $994.53 million or $4.89 per share.
| Cash & Cash Equivalents | 994.53M |
| Total Debt | n/a |
| Net Cash | 994.53M |
| Net Cash Per Share | $4.89 |
| Equity (Book Value) | 986.14M |
| Book Value Per Share | 4.85 |
| Working Capital | 976.68M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$422.89 million and capital expenditures -$201,000, giving a free cash flow of -$423.09 million.
| Operating Cash Flow | -422.89M |
| Capital Expenditures | -201,000 |
| Depreciation & Amortization | 422,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -423.09M |
| FCF Per Share | -$2.08 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Immunovant does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.37% |
| Shareholder Yield | -18.37% |
| Earnings Yield | -9.08% |
| FCF Yield | -8.28% |
Analyst Forecast
The average price target for Immunovant is $30.78, which is 20.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.78 |
| Price Target Difference | 20.33% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
